# Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin

> **NCT06030934** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 30 (estimated)

## Conditions studied

- Gastric / Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** envafolimab and lenvatinib combined with paclitaxel-albumin

## Key facts

- **NCT ID:** NCT06030934
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-24
- **Primary completion:** 2024-11-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06030934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06030934, "Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06030934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*